Status:
UNKNOWN
Implication of Cardiac Shock Wave Therapy on Coronary Artery Disease Patients
Lead Sponsor:
Beijing Hospital
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
Brief Summary
CAD is a challenging affliction which has a high annual morbidity rate in China and the world. Severe CAD may lead to compromised cardiac function, decreased exertional capacity and poor quality of li...
Detailed Description
CAD is a challenging affliction which has a high annual morbidity rate in China and the world. Severe CAD may lead to compromised cardiac function, decreased exertional capacity and poor quality of li...
Eligibility Criteria
Inclusion
- Multiple or diffused coronary artery stenosis via coronary angiography, and not the candidates for PCI or CABG;
- Myocardial ischemia documented by stressed MPI and echocardiography;
- Refractory angina that has not been alleviated after at least three months of optimal medication treatment (OMT);
- Left ventricular ejection fraction (LVEF) ≥ 30%.
Exclusion
- Acute myocardial infarction within one month;
- PCI or CABG within one month;
- Heart transplant patient;
- Patients with prosthetic valves;
- Cases of atrial or ventricular thrombosis;
- Uncontrolled heart failure with LVEF \<30%;
- Severe arrhythmia; (viii) patients with pacemakers;
- Cases of infective endocarditis;
- Chronic obstructive pulmonary disease patients;
- Pregnant or nursing women;
- Patients with silicone breast implants;
- Chest tumor patients;
- Patients already participating in other clinical trials.
Key Trial Info
Start Date :
January 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 20 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04694157
Start Date
January 20 2021
End Date
June 20 2023
Last Update
January 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Hospital
Beijing, Beijing Municipality, China, 100730